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ARTICLE OPEN
Wnt5a induces ROR1 to recruit cortactin to promote
breast-cancer migration and metastasis
Md Kamrul Hasan1, George F. Widhopf II1, Suping Zhang1,2, Sharon M. Lam1, Zhouxin Shen3, Steven P. Briggs3, Barbara A. Parker 1 and
Thomas J. Kipps1,2*
ROR1 is a conserved oncoembryonic surface protein expressed in breast cancer. Here we report that ROR1 associates with cortactin
in primary breast-cancer cells or in MCF7 transfected to express ROR1. Wnt5a also induced ROR1-dependent tyrosine
phosphorylation of cortactin (Y421), which recruited ARHGEF1 to activate RhoA and promote breast-cancer-cell migration; such
effects could be inhibited by cirmtuzumab, a humanized mAb specific for ROR1. Furthermore, treatment of mice bearing breast-
cancer xenograft with cirmtuzumab inhibited cortactin phosphorylation in vivo and impaired metastatic development. We
established that the proline at 841 of ROR1 was required for it to recruit cortactin and ARHGEF1, activate RhoA, and enhance breast-
cancer-cell migration in vitro or development of metastases in vivo. Collectively, these studies demonstrate that the interaction of
ROR1 with cortactin plays an important role in breast-cancer-cell migration and metastasis.
npj Breast Cancer            (2019) 5:35 ; https://doi.org/10.1038/s41523-019-0131-9
INTRODUCTION
ROR1 is an evolutionarily conserved, developmentally restricted
type-I receptor–tyrosine-kinase-like orphan receptor,1–4 which has
a cytoplasmic domain consisting of a tyrosine-kinase-like domain,
two serine/threonine-rich domains, and a proline-rich domain
(PRD). With few exceptions,5 ROR1 expression is the highest
during embryogenesis, diminishes during fetal development, and
becomes negligible on most postpartum tissues.6
We found that ROR1 is expressed by most human cancers,
including breast cancer, intimating that it plays a role in cancer
pathophysiology.7 In support of this proposition are findings
demonstrating that expression of ROR1 can enhance
epithelial–mesenchymal transition and cancer-cell proliferation,
migration, and metastasis.8,9 Moreover, high-level tumor-cell
expression of ROR1 associates with adverse outcome in patients
with various cancers.8,10–12
We discovered that Wnt5a can act as a ligand for ROR1,6 which
could induce activation of RhoA and enhance migration of breast-
cancer-cell lines.13,14 Recently, we described that Wnt5a could
cause ROR1 to associate with cortactin to enhance migration of
chronic lymphocytic leukemia (CLL) cells.15 In this case, cortactin
cooperates with another cytoskeletal protein named hematopoie-
tic cell-specific protein-1 (HS1) to complex with ROR1 at proline
841, and thereby enhances activation of RhoA and the migration
of CLL cells.15,16 However, HS1 is expressed primarily by
hematopoietic cells, but not breast-cancer cells.17 As such, it is
not known whether the interaction of ROR1 with cortactin can
play a role in the migration or metastasis of cancer cells
independent of HS1.
Cortactin (also known as EMS1, or CTTN) is expressed by the
neoplastic cells of a variety of different cancers and evidently
functions in cancer-cell migration and metastasis.18–22 Upon
external stimulation, cortactin undergoes tyrosine phosphoryla-
tion and then contributes to the ordered rearrangement and
polymerization of the actin cytoskeleton, which is required for cell
migration.23–27 Cortactin contains a Src-homology-3 (SH3) domain,
allowing it to bind at characteristic –P–X–X–P– motifs in the PRD
of surface-receptor proteins.28–30 Cortactin is also expressed in
breast-cancer and in breast-cancer-cell lines, such as MCF7.
Amplification of the gene encoding cortactin is observed in at
least 15% of metastatic breast carcinomas.31,32 High-level breast-
cancer-cell expression and phosphorylation of cortactin associates
with an unfavorable prognosis for patients with breast cancer.33–36
In this study, we examined whether Wnt5a could stimulate ROR1
to complex with cortactin and thereby recruit and activate
ARHGEF1 to enhance activation of RhoA and promote breast-
cancer-cell migration/metastasis.
RESULTS
Wnt5a induces ROR1 to complex with cortactin in breast-cancer
PDX
We examined eight primary breast-cancer patient-derived xeno-
grafts (PDXs) (Supplementary Fig. 1). Table 1 provides the
diagnosis, histologic grade, patient’s age and race, and tumor-
cell expression of estrogen receptors (ER), progesterone receptors
(PR), HER2, ROR1, cortactin, or Wnt5a (see also Supplementary Fig.
1). Only one PDX (PDX1) was HER2+, one (PDX5) was ER+, and six
(PDX3–8) expressed high-level ROR1. All PDX were histologic
grade 3 and expressed cortactin and Wnt5a. None of the PDX
were PR+.
Mass spectrometry (MS) analyses of anti-ROR1 mAb immune
precipitates (i.p.) from lysates of ROR1-expressing breast-cancer
PDX revealed cortactin in addition to ROR1 (Fig. 1a). Immunoblot
analyses of anti-ROR1 or anti-cortactin immune precipitates
confirmed that cortactin complexed with ROR1 in breast-cancer
PDX cells (Fig. 1b–e). However, we did not detect such
ROR1–cortactin complexes in lysates prepared from breast-
cancer–PDX cells cultured overnight in serum-free media unless
they were treated with exogenous Wnt5a (Fig. 1f, g), suggesting
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that the endogenous Wnt5a was limiting and insufficient to
maintain ROR1–cortactin complexes in vitro.
We treated the breast-cancer PDX cells with cirmtuzumab, a
humanized mAb specific for a functional epitope of ROR1 that is
distinct from the epitope recognized by the anti-ROR1-mAb 4A5,
which we used to generate the anti-ROR1 i.p. We found that
treatment of the breast-cancer PDX with cirmtuzumab blocked
Wnt5a from inducing ROR1 to complex with cortactin (Fig. 1h, i).
Wnt5a stimulates ROR1-dependent cortactin phosphorylation and
enhances the migration of breast-cancer PDX cells
Previous studies found that cortactin may be phosphorylated in
breast-cancer cells of some patients,23,31 and that high levels of
phosphorylated cortactin associated with enhanced cancer-cell
migration, metastasis, and adverse prognosis.18,20,33 We found
breast-cancer PDX that expressed high levels of ROR1 had higher
levels of Y421-phosphorylated cortactin than breast-cancer PDX
with low levels of ROR1 (Supplementary Fig. 1). Culture of breast-
cancer PDX cells in serum-free media resulted in the samples
having lower levels of Y421-phosphorylated cortactin over time
(Supplementary Fig. 2a). However, treatment of serum-starved
breast-cancer PDX cells with exogenous Wnt5a could enhance the
level of phosphorylated cortactin within 5 min (Fig. 2a, b). Because
prior studies indicated that ROR1 was a pseudokinase with activity
that was dependent on its ability to associate with other kinases,
such as Src,37,38 we examined for this by reducing expression of
Src by using specific siRNA, and found that this inhibited Wnt5a-
induced tyrosine phosphorylation of cortactin (Y421). These data
support the notion that Src contributes to Wnt5a–ROR1-depen-
dent cortactin phosphorylation (Supplementary Fig. 3).
Nonetheless, we found that cirmtuzumab could inhibit the
capacity of Wnt5a to induce tyrosine phosphorylation of cortactin
in serum-starved ROR1+breast-cancer PDX, even at Wnt5a
concentrations of 100 ng/ml (Fig. 2c, d), indicating that the
Wnt5a-induced phosphorylation of cortactin was dependent on
ROR1. We also found that cirmtuzumab could also inhibit Y421
phosphorylation of cortactin in secondary tumors generated from
primary breast-cancer PDX cells in vivo (Fig. 2e, f).
Other studies demonstrated that Wnt5a could enhance migra-
tion of breast-cancer cells.13,14 In this study, we found that Wnt5a
enhances the migration of serum-starved breast-cancer PDX cells
that expressed ROR1, and that such effects could also be blocked
by cirmtuzumab (Fig. 2g).
Wnt5a stimulates ROR1 to complex with cortactin in
MCF7–ROR1 cells
MCF7 cells were generated from breast ductal carcinoma cells and
have been used for studying breast-cancer-cell biology.8,9,13 We
found that these cells do not express ROR1, but could be made to
express ROR1 upon stable transfection with a ROR1-expression
vector, thus generating MCF7–ROR1 (Supplementary Fig. 4).8,9
Immunoblot analysis of immune precipitates by using anti-
ROR1 or anti-cortactin antibodies revealed that cortactin com-
plexed with ROR1 in MCF7–ROR1 cells (Supplementary Fig. 5a, b).
Such complexes were not detected in the i.p. of lysates from MCF7
cells, which lack detectable ROR1 (Supplementary Figs. 1a, 4 and 5c),
or lysates from MCF7–ROR1 cells cultured overnight in serum-free
media unless the cells were treated with exogenous Wnt5a
(Supplementary Fig. 5d). Treatment of MCF7–ROR1 cells with
cirmtuzumab blocked the capacity of Wnt5a to induce ROR1 to
recruit cortactin in such serum-starved MCF7–ROR1 cells (Supple-
mentary Fig. 5e).
Wnt5a stimulates ROR1-dependent cortactin phosphorylation and
increases the migration capacity of MCF7–ROR1 cells
We found that cortactin is phosphorylated at Y421 in
MCF7–ROR1 cells cultured in DMEM with 10% fetal bovine serum
(FBS). Culture of MCF7–ROR1 cells in serum-free media reduced
the levels of phosphorylated cortactin over time (Supplementary
Fig. 2b). Treatment of serum-starved MCF7–ROR1 cells, but not
MCF7 cells, with exogenous Wnt5a induced tyrosine phosphoryla-
tion of cortactin in a time-dependent manner (Supplementary Fig.
6a). However, Wnt5a could not stimulate tyrosine phosphorylation
of cortactin in MCF7–ROR1 cells treated with cirmtuzumab
(Supplementary Fig. 6b), indicating that Wnt5a-induced cortactin
phosphorylation was dependent on ROR1.
We found that treatment with Wnt5a also enhanced the
migration of MCF7–ROR1 cells (Supplementary Fig. 7a–c). We
selected the concentration of Wnt5a, 200 ng/ml, for use in our
migration assays to enhance the sensitivity for detecting
differences in the numbers of migrated cells over the time of
the assay (Supplementary Fig. 8). However, Wnt5a had only a
modest effect on the migration of MCF7, as observed in previous
studies.13 The capacity of Wnt5a to enhance migration of
MCF7–ROR1 cells specifically could be blocked by treatment with
cirmtuzumab (Supplementary Fig. 6c) or cortactin-specific siRNA,
but not nonspecific siRNA (Supplementary Fig. 6d, e). Collectively,
these studies demonstrate that Wnt5a can enhance migration of
MCF7–ROR1 cells significantly more than MCF7 cells in a ROR1/
cortactin-dependent manner.
Wnt5a stimulates ROR1/cortactin to complex with ARHGEF1 and
activate RhoA
In a prior study, we described that ROR1/cortactin complex
contributed to enhanced activation of RhoA in CLL cells.15 Here,
we examined in different cellular microenvironments whether this
complex could associate with ARHGEF1 to enhance activation of
RhoA. Immunoblot analysis of anti-cortactin or anti-ARHGEF1 i.p.
Table 1. Data on breast-cancer patient-derived xenograft (PDX), including tumor diagnosis, grade, sex, age, race, and expression information of ER
(estrogen receptor), PR (progesterone receptor), HER2, ROR1, cortactin, or Wnt5a. Here, “yes” means “expressed”, and “no” means “not expressed”
PDX samples Diagnosis Grade Sex Age Race ER PR HER2 ROR1 Cortactin Wnt5a
1 Invasive ductal carcinoma Grade 3 Female 73 White No No Yes No Yes Yes
2 Invasive ductal carcinoma Grade 3 Female 64 White No No No No Yes Yes
3 Mixed ductal carcinoma Grade 3 Female 52 White No No No Yes Yes Yes
4 Invasive ductal carcinoma Grade 3 Female 44 Asian or Pacific Islander No No No Yes Yes Yes
5 Metastatic Grade 3 Female 48 White Yes No No Yes Yes Yes
6 Invasive ductal carcinoma Grade 3 Female 70 White No No No Yes Yes Yes
7 Invasive ductal carcinoma Grade 3 Female 68 Asian or Pacific Islander No No No Yes Yes Yes
8 Invasive ductal carcinoma Grade 3 Female 32 White No No No Yes Yes Yes
Characteristics of breast-cancer patient-derived xenograft (PDX) samples
M.K. Hasan et al.
2
npj Breast Cancer (2019)    35 Published in partnership with the Breast Cancer Research Foundation
1
2
3
4
5
6
7
8
9
0
()
:,;
by using lysates made from ROR1+ breast-cancer PDX cells
revealed that ARHGEF1 associated with cortactin (Supplementary
Fig. 9a, b), and more specifically Y421-phosphorylated cortactin
(Supplementary Fig. 9c). We noted that the ARHGEF1 i.p.
generated from lysates of breast-cancer PDX treated with cortactin
siRNA had less capacity to generate activated RhoA than the
ARHGEF1 i.p. of PDX treated with control, nonspecific siRNA
(Supplementary Fig. 9d). Moreover, Wnt5a induced less RhoA–GTP
in MCF7–ROR1 cells treated with cortactin-specific siRNA than in
MCF7–ROR1 cells treated with nonspecific control siRNA (si-Ctrl)
(Supplementary Fig. 9e). Furthermore, Wnt5a-induced activation
of RhoA could be blocked by cirmtuzumab in PDX cells
M.K. Hasan et al.
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(Supplementary Fig. 9f, g). We also noted that exogenous Wnt5a
could induce activation of RhoA in MDA-MB-231 cells, which prior
studies found expressed ROR1,9 but not in MDA-MB-231 cells
silenced for ROR1 with ROR1-specific siRNA (Supplementary Fig.
10).
P841 is required for ROR1 to bind and activate cortactin/ARHGEF1
Cortactin contains a SH3 domain, which can bind to –P–X–X–P–
sites that typically are found within the PRDs of other proteins,
including ROR1.1,28–30 Previously we described that PRD or proline
at 841 of ROR1 was required for ROR1/cortactin association and
phosphorylation of cortactin in CLL cells.15 Here, we examined
whether the ROR1–PRD was necessary for ROR1 to complex with
cortactin in breast-cancer cells. Accordingly, we transfected MCF7
cells with an expression vector driving expression of either wild-
type ROR1 or a truncated ROR1 housing a deletion of the entire
PRD (ΔPRD–ROR1) (Fig. 3a, b; Supplementary Fig. 4). In contrast to
the anti-ROR1 i.p. from lysates of MCF7–ROR1 cells, the anti-ROR1
i.p. from lysates of MCF7–ΔPRD–ROR1 cells did not have
detectable cortactin (Fig. 3d).
Accordingly, we analyzed various mutants of ROR1 that each
had a substitution of alanine (A) for proline (P) at position 784,
808, 826, or 841 in one of the putative SH3-binding sites within
the ROR1–PRD (Fig. 3c; Supplementary Fig. 4). Comparable
amounts of ROR1 were expressed by MCF7 cells transfected to
express the wild-type (W/T) or any one of the ROR1 mutants (Fig.
3e; Supplementary Fig. 4). Following treatment with Wnt5a, ROR1
with a P ¼>A substitution at 784, 808, or 826 each could complex
with cortactin and recruit ARHGEF1 as effectively as the W/T ROR1
(Fig. 3e). However, the mutant with a P ¼>A substitution at 841 of
ROR1 (ROR1P(841)A) did not associate with cortactin (Fig. 3e).
We examined whether Wnt5a could induce phosphorylation of
cortactin or activation of RhoA in MCF7 cells transfected with W/T
ROR1 or any one of the ROR1 mutants. Each of the various
transfected MCF7 cell lines expressed levels of cortactin that were
comparable to that of the MCF7 parental cell line (Fig. 3f). We
observed that Wnt5a induced phosphorylation of cortactin and
activation of RhoA, and enhanced the motility of MCF7 cells
expressing ROR1 with a P ¼>A substitution at 784, 808, or 826 as
effectively as MCF7–ROR1 cells expressing W/T ROR1 (Fig. 3f, g, h).
However, Wnt5a did not induce such effects with MCF7–
ΔPRD–ROR1 cells, MCF7–ROR1P(841)A cells, or MCF7 cells, which
lacked ROR1 altogether (Fig. 3f, g, h).
P841 is required for ROR1 to enhance MCF7-metastatic
development, which can be inhibited by cirmtuzumab
Previous studies demonstrated that ROR1+ breast-cancer cells had
a greater capacity to metastasize than breast-cancer cells silenced
for ROR1.9 Consistent with these findings, we found that the
numbers of metastatic foci detected in the lungs of mice 1 (Fig. 4a,
b) or 3 weeks (Fig. 4c, d) following intravenous injection of
MCF7–ROR1 cells were significantly greater than those detected in
the lungs of mice injected with equal numbers of MCF7 cells. On
the other hand, the numbers of metastatic foci detected in mice
injected with MCF7–ROR1P(841)A cells were significantly less than
those found in mice injected with MCF7–ROR1 cells (Fig. 4a–d),
but comparable to the numbers of metastatic foci detected in
mice injected with MCF7 cells, or in mice injected with
MCF7–ROR1 cells treated at days-0 and -14 with cirmtuzumab
(10mg/kg) (Fig. 4e–h).
DISCUSSION
In the present study, we found that Wnt5a induces ROR1 to
associate with cortactin, which undergoes tyrosine phosphoryla-
tion in breast-cancer PDX cells or MCF7 cells transfected to
express ROR1. Moreover, in response to Wnt5a, ROR1/cortactin
complexed and stimulated ARHGEF1, which induced activation of
RhoA and enhanced cell migration. Silencing expression of
cortactin with cortactin-directed siRNA inhibited Wnt5a-
enhanced cell migration. Collectively, these studies demonstrate
that cortactin plays a critical role in ROR1-dependent, noncano-
nical Wnt5a signaling, leading to increased tumor-cell migration
and metastasis.
The ROR1–PRD was essential for ROR1 to complex with
cortactin and increase breast-cancer-cell migration in response
to Wnt5a. Cortactin houses a SH3 domain, permitting it to
associate with other proteins that have suitable –P–X–X–P–motifs,
which typically reside with the PRD.28–30 We found that the proline
residue at position 841 of ROR1 was indispensable for it to recruit
cortactin. Moreover, in contrast to W/T ROR1 or ROR1 with proline-
to-alanine substitutions at other sites, the mutant ROR1 with an
alanine instead of a proline at position 841 (ROR1P841A) was unable
to complex with cortactin, enhance cortactin phosphorylation,
recruit ARHGEF1, activate RhoA, or enhance cell migration/
metastasis of MCF7 cells. Thus, this residue plays an important
role for ROR1 to bind and phosphorylate cortactin, which appears
necessary to enhance migration and metastasis of
MCF7–ROR1 cells. This contrasts with our findings to CLL cells,
which also express another cytoskeletal protein named HS1. HS1
also can complex with ROR1 at proline 841 to enhance
chemokine-directed migration of CLL cells in response to
Wnt5a.15,16 HS1 is not expressed in cancers derived from non-
hematopoietic cells, such as breast cancer.17 Instead, we find that
the ROR1–cortactin interaction is critical for enhanced migration
and metastasis of breast-cancer cells independent of expression
of HS1.
Primary breast cancers that express relatively high levels of
phosphorylated cortactin have a greater capacity for migration/
metastasis and are associated with a less favorable prognosis than
breast cancers with low-to-negligible levels of phosphorylated
Fig. 1 Association of ROR1 with cortactin in breast-cancer patient-derived xenografts (PDXs). a Cortactin peptide identified by 2D-
nanoLC–MS/MS in anti-ROR1 (cirmtuzumab) immune precipitates (i.p.) of lysates of PDX4 (representative of two PDXs). b Immunoblot of i.p. by
using anti-ROR1 mAb or control IgG (Ctrl-IgG), as indicated on the top, by using lysates of PDX3 (representative of three PDXs). The bottom
panel is an immunoblot of the whole-cell lysates (WCL) probed with anti-cortactin mAb. c Black columns indicate the mean relative
interaction of cortactin with ROR1 (error bars indicate S.D.) for PDX3, PDX4, and PDX5. d Immunoblot of i.p. by using anti-ROR1 mAb or Ctrl-
IgG, as indicated on the top, by using lysates of PDX4 (representative of three PDXs). The bottom panel is an immunoblot of the WCL probed
with anti-cortactin mAb. e Black columns indicate the mean relative interaction of cortactin with ROR1 (±S.D.) for PDX3, PDX4, and PDX5. f
Immunoblot of anti-ROR1 i.p. from lysates of serum-starved PDX5 cells (representative of three PDXs) that subsequently were treated for
30min without (−) or with (+) Wnt5a (100 ng/ml), as indicated on the top. The bottom panel is an immunoblot of the WCL probed with anti-
cortactin mAb. g Columns indicate the mean relative interaction of cortactin with ROR1 (±S.D.) for PDX3, PDX4, and PDX5 that were treated for
30min without (−) or with (+) Wnt5a, as in 1f and indicated below (P < 0.001, two-tailed Student’s t test). h Immunoblot of anti-ROR1 (4A5) i.p.
by using lysates of serum-starved PDX5 (representative of three PDXs) that had been treated with Ctrl-IgG or cirmtuzumab (10 μg/ml) for 2 h,
and subsequently treated for 30min without (−) or with (+) Wnt5a (100 ng/ml), as indicated above. i Columns indicate the mean relative
interaction of cortactin with ROR1 (±S.D.) for PDX3, PDX4, and PDX5 that had been treated with Ctrl-IgG or cirmtuzumab, without (−) or with
(+) Wnt5a, as in 1 h, and indicated below (P < 0.01, two-tailed Student’s t test)
M.K. Hasan et al.
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cortactin.33–36 Factors other than Wnt5a, such as activation of Src-
family kinases, may also induce cortactin phosphorylation in
breast-cancer cells.39,40 However, our findings indicate that
phosphorylation of cortactin may also be in response to Wnt5a,
which is generally present at high levels in breast carcinomas
relative to that noted in normal breast tissues.41,42 Consistent with
this notion, we found that the level of phosphorylated cortactin
rapidly attenuated in breast-cancer PDX cultured in serum-free
Fig. 2 Wnt5a induces ROR1-dependent phosphorylation of cortactin and enhances migration of breast-cancer PDX cells. a Immunoblot
analysis of lysates prepared from serum-starved PDX5 (representative of three PDXs) that subsequently were treated with Wnt5a (100 ng/ml)
for the times indicated above (in minutes). b Columns indicate the mean relative tyrosine phosphorylation of cortactin at Y421 (pCortactin)
(±S.D.) for PDX4, PDX5, and PDX6 treated for 0, 1, or 5 min with Wnt5a (P < 0.05, two-tailed Student’s t test). c Immunoblot analysis of lysates
prepared from serum-starved PDX5 (representative of three PDXs) that subsequently were treated with Ctrl-IgG or cirmtuzumab (10 μg/ml),
without (−) or with (+) Wnt5a, as indicated above. d Columns indicate the mean relative pCortactin (±S.D.) for PDX4, PDX5, and PDX6 cells
treated with Ctrl-IgG or cirmtuzumab for 2 h, and subsequently treated for 5min without (−) or with (+) Wnt5a, as indicated below (P < 0.01,
Student’s t test). e Immunoblot analysis of lysates of PDX4 harvested from mice treated with Ctrl-IgG or cirmtuzumab (10mg/kg), as indicated
on top, and probed for pCortactin or Cortactin, as indicated on the left. f Columns indicate the mean relative pCortactin (±S.D.) for PDX3,
PDX4, and PDX5 (P < 0.01, two-tailed Student’s t test). g Columns indicate the mean cell migration at 10 h (±S.D.) in the absence (−) or
presence (+) of exogenous Wnt5a (200 ng/ml) for serum-starved PDX4, PDX5, and PDX6 that were treated with Ctrl-IgG or cirmtuzumab
(10 μg/ml). Data are from three independent experiments (P < 0.05; P < 0.01, Student’s t test)
M.K. Hasan et al.
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media unless we added exogenous Wnt5a. We find that Wnt5a
induces phosphorylation of cortactin at Y421 via ROR1 signaling,
which may be dependent on the activity of Src.37,38 In any case,
our results reveal that the association of cortactin phosphorylation
with metastasis may reflect differences in Wnt5a-induced ROR1-
dependent signaling. Consistent with this notion are studies
demonstrating that high-level expression of ROR1 in breast cancer
is associated with increased rates of metastases and poorer
survival.8,9
We previously found that Wnt5a could induce ROR1 to recruit
and activate ARHGEF1, leading to activation of RhoA in leukemia
cells.43 However, the mechanism for this was unclear, as ARHGEF1
does not contain an SH3-binding domain. Here we demonstrate
that association of ARHGEF1 to ROR1 appears mediated by
cortactin. In this light, cortactin may be considered an adaptor
protein for ROR1, functioning to enhance cell migration and/or
metastasis by recruiting and activating ARHGEF1 to ROR1 to
provide localized activation of RhoA.44 Consistent with this model
Fig. 3 ROR1P(841)A fails to associate with cortactin, induce phosphorylation of cortactin, or enhance migration of MCF7 cells. a Schematic
depicts the structure of ROR1 protein with different domains. b ΔPRD represents the truncated form of ROR1 without its proline-rich region
(PRD). c Amino acid sequences of the PRD of ROR1. Asterisks indicate the proline (P) residues that were replaced with alanine (A). d
Immunoblots of anti-ROR1 i.p. by using lysates of MCF7 (Ctrl), MCF7–WT ROR1, or MCF7 cells transfected with ROR1–ΔPRD, as indicated on
the top, and probed with antibodies specific for ROR1 or cortactin, as indicated on the left. An immunoblot of the WCL probed with anti-
cortactin mAb is in the bottom panel. e Immunoblots of anti-ROR1 i.p. by using lysates of MCF7-Ctrl, MCF7–ΔPRD, MCF7–WT ROR1, or MCF7
transfected with each of the various mutated forms of ROR1, as indicated on the top, and probed with antibodies specific for ROR1, cortactin,
or ARHGEF1, as indicated on the left. An immunoblot of the WCL probed with anti-cortactin is in the bottom panel. f Immunoblots of lysates
prepared from serum-starved MCF7 (Ctrl), MCF7–ΔPRD, MCF7–WT ROR1, or MCF7 cells transfected with each of the various mutated forms of
ROR1, as indicated on top, which subsequently were treated without (−) or with (+) Wnt5a (100 ng/ml), as indicated on the top; the
membranes were probed with antibodies specific for ROR1, Cortactin, or pCortactin, as indicated on the left. g Immunoblot of activated RhoA
(RhoA–GTP, top panel) or total RhoA (RhoA total, bottom panel) found in lysates of MCF7 (Ctrl), MCF7–ΔPRD, MCF7–WT ROR1, or MCF7
expressing any one of the various mutant forms of ROR1, as indicated on top of each lane in Fig. 1f. h Columns indicate the mean number of
migrated cells at 10 h of MCF7 (Ctrl), MCF7–ΔPRD, MCF7 expressing any one of the various mutant forms of ROR1, or MCF7–WT ROR1, as
indicated below, which were serum-starved and then examined for migration without (−) or with (+) Wnt5a (200 ng/ml), as indicated at the
bottom. Data are shown from three independent experiments (P < 0.05; P < 0.01, as calculated by one-way ANOVA with Bonferroni’s multiple-
comparison test).
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is the observation that breast-cancer cells with reduced levels of
cortactin following treatment with cortactin-specific siRNA had
reduced chemotaxis in response to Wnt5a, implicating that cortactin
plays a critical role in breast-cancer-cell migration/metastasis.
One study found that Wnt5a could also enhance macrophage-
induced invasiveness of MCF7 cells in vitro.45 Furthermore,
another study found that forced expression of Wnt5a enhanced
activation of RhoA in 21PT and 21NT breast-cancer-cell lines, but
only increased cellular motility in 21NT cells.46 As noted in the
present study, MCF7 cells lack expression of ROR1, suggesting that
some of the effects of Wnt5a on cell invasiveness may be
independent of ROR1. In any case, our study indicates that Wnt5a
Fig. 4 Proline at 841 of ROR1 is critical for enhancing development of metastatic foci of MCF7–ROR1. a HE staining of lung tissue from a
representative tumor-bearing mouse engrafted with MCF7 or MCF7-expressing ROR1 (MCF7–ROR1) or the mutant form of ROR1, ROR1P841A
(MCF7–P841A) at 1 week after intravenous (i.v.) tail-vein injections of equal numbers of viable cells. Green arrows indicate metastatic foci
(objective: 40×). b Each symbol represents the number of metastatic foci that were found in the lungs of each animal in the groups indicated
below (mean ± S.D., n= 5). P < 0.01; P < 0.05, two-tailed Student’s t test. c HE staining of lung tissue of mice injected as in (a), but 3 weeks after
i.v. injection of equal numbers of viable cells, as indicated on top. Green arrows indicate metastatic foci (objective: 40×). d Each symbol
represents the number of metastatic foci found in the lungs of each mouse per group (mean ± S.D., n= 5). P < 0.001; P < 0.01, as assessed by
two-tailed Student’s t test. e HE staining of lung tissue from a representative tumor-bearing mouse injected i.v. with MCF7–ROR1 cells 1 week
earlier and treated with nonspecific human IgG (IgG) or cirmtuzumab (10mg/kg), as indicated on top. Green arrows indicate metastatic foci
(objective: 40×). f Each symbol represents the number of metastatic foci that were found in the lungs of each animal in each group (mean ± S.D.,
n= 5) (P < 0.05, two-tailed Student’s t test). g HE staining of lung tissue from a representative tumor-bearing mouse injected i.v. with
MCF7–ROR1 cells 3 weeks earlier and treated with nonspecific human IgG (IgG) or cirmtuzumab (10mg/kg), as indicated on top. Green arrows
indicate metastatic foci (objective: 40×). h Each symbol represents the number of metastatic foci that were found in the lungs of each animal
in each group (mean ± S.D., n= 5 (P < 0.01, two-tailed Student’s t test)).
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induces ROR1-dependent cortactin phosphorylation, which prior
studies found could associate with the Arp2/3 complex to facilitate
cytoskeletal reorganization, stabilized branched actin networks,
and lamellipodia formation to enhance cellular motility.25,47,48
In conclusion, the present study demonstrates a previously
unrecognized ROR1/cortactin/ARHGEF1-dependent pathway lead-
ing to activation of RhoA in response to Wnt5a in breast-cancer
cells. The reported findings highlight a pathway for potential drug
development targeting ROR1-dependent Wnt5a-induced signal-
ing. In this regard, we found that cirmtuzumab could block the
capacity of Wnt5a to induce ROR1 to complex and phosphorylate
cortactin, recruit ARHGEF1, and activate RhoA, thereby suppres-
sing breast-cancer-cell migration/metastasis. It should be noted
that in these studies, cirmtuzumab was injected on the same day
on which mice were challenged with cancer cells injected
intravenously to study the effect of blocking ROR1 signaling on
circulating breast-cancer cells. Other studies have demonstrated
that treatment with cirmtuzumab may mitigate the risk for relapse
and metastasis of breast-cancer PDX treated with paclitaxel.49
Clinical studies are underway to examine the safety and activity of
cirmtuzumab used in combination with paclitaxel for treatment of
patients with advanced breast cancer (https://clinicaltrials.gov/ct2/
show/ NCT02776917). Such studies will be required to determine
whether cirmtuzumab may have activity in patients with
established metastases. In any case, this study provides added
rationale for the clinical evaluation of this humanized anti-ROR1
mAb in the treatment of patients with breast cancer or other
ROR1-expressing cancers.50,51
METHODS
Cell culture
MCF7, MDA-MB-231 cells (purchased from ATCC), or MCF7 cells transfected
with different ROR1 constructs, were cultured in DMEM medium with 10%
FBS, 1% penicillin/streptomycin, maintained at 37 °C in a humidified
atmosphere of 5% CO2, and tested negative for mycoplasma contamina-
tion. Media and supplements were purchased from Life Technologies
(Carlsbad, CA, USA).
For serum starvation of breast-cancer PDX cells, freshly isolated PDX cells
were cultured in mammary–epithelial basal medium without growth
factors, purchased from Lonza.
Immunoprecipitation analysis
Immunoprecipitation analysis was performed as described.52 Cells were
lysed in a buffer containing 1% Nonidet P-40, 10 mM Tris-HCl (pH 7.5),
50mM NaCl, and 1mM EDTA with protease inhibitors (Roche). The lysates
were cleared by centrifugation at 16,000 × g for 15 min. Immune
precipitates were isolated by using protein A agarose beads, followed by
immunoblot or MS analysis. Antibodies for immune precipitation were as
follows: the anti-ROR1 antibodies (cirmtuzumab, or 4A5 unless specified)
were generated in our laboratory; the anti-cortactin or ARHGEF1 antibody
was obtained from Cell Signaling Technology.
Immunoblot analysis
Immunoblot analysis was performed as described.52 Briefly, cells were
washed with phosphate-buffered saline (PBS) and suspended in lysis buffer
(1% Nonidet P-40, 1 mM EDTA, 50mM NaCl, and protease inhibitors
(Roche) in 10mM Tris-HCl (pH 7.5)). The cell lysates were cleared by
centrifugation at 16,000 × g for 15 min and used for immunoblot analysis
or for preparing immune precipitates with specific antibodies, which were
isolated with protein A agarose. Proteins were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis and electrophoretically
blotted onto polyvinylidene difluoride membrane (Immobilion-P, Milli-
pore). Immunoblot analysis was performed by using primary antibodies
specific for cortactin (Cell Signaling Technology, Danvers, MA, USA; dilution
1:1000, catalog#3503), phospho-cortactin (Y421) (Cell Signaling; dilution
1:500, catalog#4569), ARHGEF1 (Cell Signaling; dilution 1:1000, cata-
log#3669), β-actin (Cell Signaling; dilution 1:1000, catalog#8457), Src (Cell
Signaling; dilution 1:1000, catalog#2109), or ROR1 (Cell Signaling; dilution
1:1000, catalog#4102), which were detected with horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling). The integrated optical
density (IOD) of bands was evaluated by densitometry and analyzed by
using Gel-Pro Analyzer software (Media Cybernetics). All the samples for
the same experiment were prepared at the same time, and blots were
processed in parallel.
Nucleofection of plasmids and siRNA
Cell line Nucleofector Kit for siRNA or plasmid transfection was purchased
from Lonza. Cells (2 × 106) were suspended in 100 μl of Nucleofector
Solution with plasmids (pcDNA3.1 vector expressing human ROR1) or
siRNAs (GE Dharmacon, Lafayette, CO) and transfected with the
Nucleofector II device (program P-020). The transfected cells were cultured
in six-well plates in complete medium for 48 (plasmids) or 72 h (siRNA) and
then subjected to immunoblot analysis and assays. Endofree Plasmid Maxi
Kits (QIAGEN) were used to purify plasmids for transfection. G418 (800 μg/
ml) was used for selection of stable MCF7 transfectants, which were then
examined via flow cytometry or western blot.
MS analysis
MS analysis was performed as described previously.52 Briefly, bound
proteins were digested by trypsin (Roche) directly on beads for the MS
analysis. Digested peptides were separated by online 2D-nanoLC and
detected by LTQ linear ion-trap mass spectrometers. Each sample took
22.5 h to analyze, and about 200,000 MS/MS spectra were collected for
each run. Raw data were extracted and searched by using Spectrum Mill
(Agilent, v3.03) database search software against the NCBI ref seq database
limited to human taxonomy (version 44).
RhoGEF nucleotide exchange activity assay
RhoGEF exchange assay kit was purchased from Cytoskeleton and used as
per the manufacturer’s instructions. For in vitro guanine nucleotide
exchange activity on RhoA, ARHGEF1 was immunoprecipitated from
MCF7–ROR1 cells that previously transfected with si-Ctrl or si-Cortactin.
Reactions were measured in a Tecan Spectrofluor plus fluorimeter (λex=
360 nm, λem= 460 nm). Pull-down ARHGEF1 was added after 120 s.
Readings were taken at 20 °C every 1 min for a total reaction time of
44min. The exchange curve can be achieved by exporting raw data to
Microsoft Excel and analyzing the data by using GraphPad Prism 6.0.
RhoA activation assay
RhoA activation assay reagents were purchased from Cytoskeleton and
used as per the manufacturer’s instructions. Briefly, GTP-bound active
RhoA was pulled down with Rhotekin-RBD beads for 1 h at 4 °C, and then
subjected to immunoblot analysis. Immunoblots of whole-cell lysates were
used to assess for total RhoA. The IOD of bands was evaluated by
densitometry and analyzed by using Gel-Pro Analyzer software (Media
Cybernetics).
Flow cytometry analysis
Flow cytometry analysis was performed as described.52 Anti-ROR1 mAb
(4A5) conjugated with Alexa Fluor 647 (4A5–Alexa Fluor 647) generated in
our laboratory was used to stain cells at 4 °C for 20min. The stained cells
were washed twice with FACS buffer (PBS, pH 7.4, 3% FBS) and examined
by 4-color, multiparameter flow cytometry by using a dual-laser
FACSCalibur (BD Biosciences). Data were analyzed by using FlowJo
software (TreeStar).
Site-specific mutation
Site-specific mutations were performed as described previously.53 In brief,
mutation constructs were generated with QuikChange Site-Directed
Mutagenesis System (Invitrogen) on the basis of the parental construct
(wild-type ROR1), according to the manufacturer’s instructions. The
mutations for each construct were verified by DNA sequencing.
The following primer sets were used:
P(784)A, 5′-CAGTGAGTAATCTCAGTAACGCCAGATATC-3′ (sense) and 5′-C
ATGTAATTAGGATATCTGGCGTTACTGAG-3′ (antisense);
P(808)A, 5′-GATTGCTGGTTTCATTGGCGCGCCAATACC-3′ (sense) and 5′-G
GTTCTGAGGTATTGGCGCGCCAATGAAACC-3′ (antisense);
P(826)A, 5′-CAATGGATACCCAATACCTGCTGGATATGCAGC-3′ (sense) and
5′-GGAAACGCTGCATATCCAGCAGGTATTGG-3′ (antisense);
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P(841)A, 5-CCAGCCAACAGGTGCTCCCAGAGTGATTC-3 (sense) and 5-GC
TGAATCACTCTGGGAGCACCTGTTGG-3 (antisense).
Cell migration assay
The cell migration assay was performed as described.13,53,54 Briefly, cells
were collected by treatment with trypsin/EDTA solution, washed twice
with serum-free medium, centrifuged, resuspended in medium containing
0.1% bovine serum albumin, and then placed in media at a concentration
of 2.5 × 104/mL; each cell suspension was placed onto separate top
chambers of a transwell culture polycarbonate insert with 6.5-mm
diameter and 8 μm of pore size (Corning). We added Wnt5a at 200 ng/
ml in the lower compartment of the chamber. After incubation at 37 °C for
10 h, wells were washed with PBS and fixed with 4% paraformaldehyde.
The cells on the apical side of each insert were removed by scraping. Cells
that migrated through the pores to the lower chamber were stained with
Diff-Quick staining kits (IMEB Inc., San Marcos, CA). Stained cells were
analyzed by counting under the Nikon inverted microscope.
Animal and PDX models
In total, 4- to 6-week-old female Rag2−/−γc
−/− mice were used in this
study, following the care and use of laboratory animal guidelines of the
National Institutes of Health (NIH). The mice were housed in laminar-flow
cabinets under specific pathogen-free conditions and fed ad libitum.
The PDX models were established by using mechanically minced fresh
breast-cancer specimens.55–57 Early passages of primary-tumor tissues
from these PDX models were mechanically minced, and enzymatically and
mechanically dissociated by using GentleMACS Dissociator (Miltenyi
Biotec) in accordance with the manufacturer’s protocol. Dead cells and
erythrocytes were removed through density-gradient centrifugation by
using Percoll Plus (CC-17-5442-01; GE Healthcare Life Sciences) following
the manufacturer’s protocol.
To test the effects of cirmtuzumab on the tyrosine phosphorylation of
cortactin (Y421) in the engraftment of primary breast tumors, 1 × 106 single
cells isolated from PDX tumors were suspended in mammary–epithelial
growth medium, mixed with Matrigel (BD Biosciences, San Diego, CA) at 1:1
ratio, and injected into the mammary pad of 4- to 6-week-old Rag2−/−γc
−/−
mice. When tumor size reached 200mm3, 10mg/kg of cirmtuzumab or Ctrl-
IgG was injected intravenously biweekly for 1 month. PDX tumors were
isolated, lysed, and examined by western blot.
Metastasis assay
To measure the metastatic potential of MCF7 and various MCF7
transfectants, the cells were injected intravenously into 4- to 6-week-old
Rag2−/−γc
−/− mice treated with estrogen pellets (17β-estradiol, Innovative
Research of America, Florida, USA), which were placed subcutaneously in
the intrascapular region as described.58 MCF7-Ctrl, MCF7–ROR1, or
MCF7–P841A cells (1 × 106) were injected intravenously (i.v.) through the
lateral tail vein in 100 µl of PBS. At the indicated times (1 or 3 weeks after
the injection of cells), the mice were euthanized, and their lungs were
removed, fixed, and stained with H&E. Metastatic foci were counted by
using Nikon microscope (Japan), objective 40×.
To examine the effect of antibodies on the capacity to generate
metastatic foci, MCF7–ROR1 cells (1 × 106) were injected intravenously (i.v.)
through the lateral tail vein in 100 µl of PBS. Mice received mg/kg of either
Ctrl-IgG or cirmtuzumab on days-0 and -14 at 10mg/kg via the tail vein
(i.v.). At the indicated times (1 or 3 week after the injection of the
MCF7–ROR1 cells), the mice were euthanized, and their lungs were
removed and fixed in formalin for pathology review, as described in the
preceding paragraph.
Statistical analysis
Data are shown as mean ± S.D. Unpaired two-tailed Student’s t test was
used to determine the differences between two groups. One-way ANOVA
with Bonferroni’s multiple-comparison test was used to calculate the
differences between multiple groups of cells. All P values < 0.05 were
considered significant. GraphPad Prism 6.0 (GraphPad Software Inc.) was
used to perform analysis for significance.
Study approval
Primary breast-tumor specimens were collected from patients, who provided
written informed consent on a protocol approved by the Institutional Review
Board of the University of California, San Diego (approval number 090401), in
accordance with the Declaration of Helsinki. The animal study protocol was
approved by the University of California San Diego Institutional Animal Care
and Use Committee (approval number S03037).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data generated and analyzed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.9874493.59 Datasets supporting the
figures and tables in this published article are not publicly available to protect patient
privacy, but can be accessed from the corresponding author on request, upon the
completion of a Data Usage Agreement, as described in the data record above. Raw
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